What Orion Pharma does

Orion Pharma is the consumer-facing brand of Orion Corporation, a Finnish pharmaceutical company founded in 1917 by three pharmacists and now publicly listed on Nasdaq Helsinki under ticker ORNBV. Orion Corporation, headquartered in Espoo, Finland, develops, manufactures and markets human and veterinary medicines, active pharmaceutical ingredients, generics and biosimilars, and a Scandinavian-focused portfolio of OTC medical devices and self-care products sold under brands including AcidDuo, Bevita Eye, Melatonin Orion Pharma, Oriptan, Pronaxen, Pyrvin, Revaxör and Stérimar. The company employs more than 3,500 people across 30+ countries and distributes its products in over 100 countries.

Core R&D is concentrated in two therapeutic areas: oncology and pain. The lead pipeline asset is ODM-212, a proprietary TEAD inhibitor in the Phase 1b/2 TEADCO clinical trial evaluating combination regimens in malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. Beyond oncology and pain, Orion's prescription portfolio spans respiratory (asthma/COPD, allergic rhinitis), neurology (epilepsy, neuropathic pain), psychiatry (schizophrenia, bipolar disorder), gastroenterology (ulcerative colitis), and urology (prostate cancer). The self-care and veterinary businesses extend the company's reach into consumer pharmacy shelves and animal health respectively.

Orion generates revenue through one-time sales across prescription pharmaceuticals, OTC/self-care products, veterinary medicines, generics/biosimilars, and B2B API supply. Commercial reach is executed via field sales representatives engaging healthcare professionals, distributor networks for global Rx distribution, retail and online pharmacy chains (Apotea, Apoteket.se, Apotek Hjärtat, Kronans Apotek, DOZ Apotek, MEDS) for OTC products in Scandinavia, and the Well by Orion Pharma e-commerce storefront for direct-to-consumer self-care. The company is also a founding member of the Apheris ADMET Network, a federated AI initiative for collaborative drug-discovery model training alongside Lundbeck, Recursion and Servier.

Name

Orion Pharma

Legal name

Orion Corporation

Website

https://orionpharma.se

Company type

Public

Founded year

1917

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Orion Corporation is a Finnish pharmaceutical company (founded 1917, Nasdaq Helsinki: ORNBV) developing, manufacturing and marketing prescription drugs focused on oncology and pain, generics and biosimilars, OTC self-care products, veterinary medicines, and APIs, serving patients, healthcare professionals and consumers across over 100 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

akta.pro secondary industries

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays) (CRADAMAG), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Eye, Ear & Nasal Care (HLAIADAF), Sleep, Stress & Mood Support (HLAIADAG), Animal Health OTC Retail (Parasite Control, Basic Care) (HLAMAIAJ), Compounding Pharmacies (Veterinary) (HLAMAIAD)

Keywords

• Prescription pharmaceuticals
• Oncology drug development
• Pain management medicines
• OTC self-care products
• Active pharmaceutical ingredients

Headquarters

HQ city

Danderyd

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Pharmaceuticals: Orion develops, manufactures and markets prescription medicines covering multiple therapy areas including oncology, pain, respiratory (asthma/COPD), neurology (epilepsy, schizophrenia, bipolar disorder), and gastroenterology (ulcerative colitis). Products are distributed through pharmacies and healthcare providers globally.
2. OTC/Egenvård Products: Self-care/OTC products including AcidDuo (heartburn), Bevita Eye (dry eyes), Melatonin Orion Pharma (jet lag), Oriptan (migraine), Pronaxen (pain), Pyrvin (pinworm), Revaxör (ear wax), and Stérimar (nasal spray). Sold through pharmacies and online pharmacy retailers across Scandinavia.
3. Veterinary Medicines: Orion develops and manufactures veterinary pharmaceutical products for animal health.
4. Generic and Biosimilar Drugs: Cost-saving generic and biosimilar pharmaceuticals complementing innovative originator products.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Orion Pharma develops, manufactures, and markets pharmaceutical products for humans and animals, with research and development focused on oncology and pain. The company offers a diversified portfolio including prescription drugs, generic and biosimilar medicines, OTC/self-care products (acid reflux, dry eyes, migraine, pain, jet lag, ear/nasal care), veterinary medicines, and active pharmaceutical ingredients supplied to other pharmaceutical companies. Products are available in over 100 countries globally, with OTC brands distributed through pharmacy chains across Scandinavia.

Product overview

Orion Pharma is a Finnish pharmaceutical company operating globally with products in over 100 countries. The company offers a diversified portfolio consisting of prescription medications (with focus on pain and oncology), generic drugs and biosimilars, active pharmaceutical ingredients, veterinary pharmaceuticals, and consumer self-care products. The self-care portfolio includes OTC medical devices and medications sold through pharmacies and online pharmacies across Scandinavia, comprising AcidDuo (heartburn relief), Bevita Eye (dry eye treatment), Melatonin Orion Pharma (jet lag relief), Oriptan (migraine treatment), Pronaxen (pain relief), Pyrvin (pinworm treatment), Revaxör (ear care), and Stérimar (nasal spray with natural seawater), all available under the Orion Pharma brand. The company also operates Well by Orion Pharma as an e-commerce platform for wellness products. Orion's prescription drug development focuses primarily on pain and oncology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• AcidDuo OTC medical device: chewable tablets that form a protective barrier against stomach acid to relieve heartburn and acid reflux. Sold to consumers through pharmacies across Scandinavia.
• Bevita Eye OTC medical device: eye drops and ointment for dry eye symptoms, containing hyaluronic acid and vitamin A to moisturize and protect the eye surface. CE-marked, sold through pharmacies.
• Melatonin Orion Pharma 3 mg and 5 mg OTC medication: melatonin tablets for short-term treatment of jet lag in adults, helping reset the body's internal clock after crossing time zones.
• Oriptan (sumatriptan) OTC medication: 50 mg sumatriptan tablets for acute migraine attacks with or without aura. Recept-free (non-prescription) OTC format.
• Pronaxen (naproxen) OTC medication: naproxen tablets providing pain relief, fever reduction, and anti-inflammatory action for adults and adolescents from 12 years for mild to moderate acute pain including menstrual cramps, headache, toothache, muscle and joint pain.
• Pyrvin (pyrvinium embonate) OTC medication: film-coated tablets for treatment of threadworm (pinworm) in children and adults, administered as a single dose repeated after two weeks.
• Revaxör OTC medical device: earwax-removing spray and drops plus caring oil for earwax and earwax plug removal. CE-marked, sold through pharmacies.
• Stérimar OTC medical device: nasal spray with natural seawater from Cancale Bay in Brittany, France, for nasal cleansing and moisturizing. Suitable for infants, children, adults, and during pregnancy. CE-marked.
• Well by Orion Pharma E-commerce platform offering curated self-care products including dietary supplements and skincare, rooted in Nordic values, providing advice and knowledge for everyday wellness.
• ODM-212 Prescription oncology drug candidate: a potential best-in-class TEAD inhibitor molecule for treatment of advanced solid tumors including malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. Currently in Phase 1b/2 clinical trials (TEADCO study).
• Prescription pharmaceuticals (pain and oncology focus) Prescription drug portfolio covering pain and oncology as core focus areas, along with products for asthma/COPD, allergic rhinitis, neurology (epilepsy, schizophrenia, bipolar disorder), psychiatry, gastroenterology (ulcerative colitis), and prostate cancer. Includes generic drugs and biosimilars.
• Veterinary pharmaceuticals Animal health medications developed and manufactured by Orion, contributing to the wellbeing of animals and pet owners.
• Active pharmaceutical ingredients (APIs) B2B offering: active pharmaceutical ingredients manufactured and supplied to other pharmaceutical companies globally.

Quantifiable outcome

• Products available in over 100 countries
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Leading Global Research InstitutescoreStrategic or Co-development PartnerOrion collaborates closely with leading global research institutes for drug discovery and development, particularly in oncology and pain therapeutic areas.
• Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerOrion partners with other pharmaceutical companies for co-development and commercialization of pharmaceutical products and therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Stada Arzneimittel: German-headquartered European pharma combining generics, specialty pharmaceuticals, and consumer health/OTC products. Highly comparable mix of branded and generic/OTC across European markets.
• Galenica: Swiss pharmaceutical and consumer health company combining pharmacy distribution with branded OTC and prescription products — overlaps with Orion's Nordic pharmacy-channel-driven OTC franchise model.
• Almirall: Spanish specialty pharmaceutical company combining prescription dermatology products with OTC/self-care offerings across European markets — comparable European mid-cap pharma with similar Rx + OTC portfolio structure.
• Grünenthal: Privately-held German specialty pharmaceutical company focused on pain management — directly overlaps with Orion's stated pain therapy R&D focus area and has similar European mid-cap pharma profile.
• Faes Farma: Spanish pharmaceutical and OTC consumer health company with a similar mix of branded prescription products and consumer self-care lines across European and Latin American markets.
• H. Lundbeck: Danish specialty pharmaceutical company of similar mid-cap size focused on central nervous system disorders; co-founding partner with Orion in the Apheris ADMET Network. Closely comparable European mid-cap pharma with branded prescription drug focus.
• Recordati: Italian mid-cap pharmaceutical company with a comparable diversified portfolio spanning specialty prescription pharmaceuticals, OTC/self-care products, and rare diseases — the closest structural analog to Orion's prescription-plus-OTC dual model.
• Ipsen: French specialty pharmaceutical company with growing oncology and pain/neuroscience focus. Comparable European mid-cap pharma with branded specialty prescription drug model and similar therapeutic area overlap with Orion.

Broad incumbents

• Perrigo: Large global OTC-focused pharmaceutical company with consumer self-care portfolio covering eye care, nasal, pain relief, and ear care categories — directly comparable OTC product categories to Orion's Scandinavian OTC range (Bevita Eye, Stérimar, Pronaxen, Revaxör).
• Viatris: Global pharmaceutical company with leading generics and biosimilars franchise plus branded specialty products — directly comparable to Orion's generic/biosimilar revenue stream and broader diversified pharma model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/orionpharmaskandinavien

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orion Pharma